Rejuveron Life Sciences finished last year with some operational but exciting activity: we moved to our new premises! The 1000 sqm on the 8th floor of the new building of the “Wagi” complex in Schlieren-Zürich are split between laboratory space and open space offices. The office space is designed to facilitate communication and stimulate innovation and creativity reflected by architectural tricks to create open office spaces interspaced with themed meeting rooms and quiet rooms, and an inviting area for team lunches at the long tavola. The design of the entire incubator space reflects our core topic: healthy aging. Our meeting rooms are named after some of the most long-lived animals on earth: immortal jellyfish, bowhead whale or galapagos tortoise. Our credo “Age better, live longer” illuminates our 9 Hallmarks of Aging wall and reminds us every day of our mission.
About Rejuveron
Rejuveron is a clinical-stage biotechnology company creating therapies to improve healthy aging. Its experienced drug discovery and development team applies a deep understanding of the biology of aging, alongside technological advances in biopharmaceutical R&D, to progress a new generation of medicines that will help people to age better and live longer.
Through its programs, each uniquely focused on preventing, repairing, or reversing the hallmarks of aging, Rejuveron is advancing a therapeutic pipeline that ranges from drug discovery to the clinic. Rejuveron’s business model is to create or acquire innovative programs, each being held within a wholly owned or majority-owned company.
The current portfolio is diversified across modalities, stages, as well as aging hallmarks, and includes a revolutionary small molecule approach to regenerate endogenous stem cell, currently in a Phase 1/2a in the USA in retinitis pigmentosa patients; a novel drug combination therapy for sarcopenia in a Phase 1b human trial.
Rejuveron has headquarters and state-of-the-art laboratories in Switzerland’s biotech hub in Bio-Technopark Schlieren, Zürich with Abu Dhabi operations in the process of being set up. Its current portfolio includes: Endogena Therapeutics (Switzerland, USA & Canada), Rejuveron Senescence Therapeutics (Switzerland & Spain), Rejuveron Vascular Therapeutics (Switzerland), Rejuveron Telomere Therapeutics (Switzerland), Rejuvenate BioMed (Belgium) and Boost Neuroscience (US).
Co-founded in 2019 by entrepreneurial scientist, Matthias Steger, and visionary investor, Christian Angermayer, Rejuveron has state-of-the-art incubator laboratory facilities and offices at its headquarters in Zürich’s Bio-Technopark (Switzerland) as well as program teams located in the USA, Canada, Spain and Belgium.
